FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2795435087> ?p ?o ?g. }

• W2795435087 endingPage "629" @default.
• W2795435087 startingPage "621" @default.
• W2795435087 abstract "To evaluate the efficacy, safety, and injection frequency of vascular endothelial growth factor (VEGF) antagonists in the treatment of macular edema secondary to retinal vein occlusion (RVO) in clinical practice.A multicenter retrospective study of the medical records of 165 patients (95 branch RVO, 70 central RVO) treated with at least three anti-VEGF injections in the study eye was conducted. Available data collected for at least 6 months after the first injection included Snellen best-corrected visual acuity (BCVA), central retinal thickness (CRT) by time-domain optical coherence tomography (TD-OCT) or spectral-domain optical coherence tomography (SD-OCT), anti-VEGF injections, other treatments/procedures for RVO, and adverse events.At baseline prior to anti-VEGF treatment, mean BCVA was 20/80 Snellen equivalent and mean CRT was 499 μm. Mean number of anti-VEGF injections received was 7.1 during the first year, 5.4 during the second year, and 5.9 during the third year; 51.3% (842/1,641) of injections were ranibizumab, 44.1% (724/1,641) were bevacizumab, and 4.6% (75/1,641) were aflibercept. One in five patients received concomitant focal laser treatment. The percentage of patients achieving both BCVA of 20/40 or better and CRT ≤250 μm on TD-OCT or ≤300 μm on SD-OCT at the same visit (primary endpoint) was 26.1% (30/115) after the first anti-VEGF injection and ranged from 20.0% (7/35) to 36.7% (11/30) after the first 16 injections. After each anti-VEGF injection from the 1st to the 16th, <60% of patients achieved 20/40 or better BCVA and ≤70% of patients achieved CRT ≤250 μm on TD-OCT or ≤300 μm on SD-OCT. The most common treatment-related adverse event was blurry or cloudy vision.In this real-world study, a mean of five to seven anti-VEGF injections was administered yearly, and the response to anti-VEGF therapy was suboptimal in many patients. Anti-VEGF therapy was well tolerated." @default.
• W2795435087 created "2018-04-13" @default.
• W2795435087 creator A5008691406 @default.
• W2795435087 creator A5010511809 @default.
• W2795435087 creator A5017424349 @default.
• W2795435087 creator A5026181496 @default.
• W2795435087 creator A5065829361 @default.
• W2795435087 date "2018-04-01" @default.
• W2795435087 modified "2023-09-30" @default.
• W2795435087 title "Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)" @default.
• W2795435087 cites W1668980245 @default.
• W2795435087 cites W1866379461 @default.
• W2795435087 cites W1971399814 @default.
• W2795435087 cites W1975926216 @default.
• W2795435087 cites W1976154023 @default.
• W2795435087 cites W1978704499 @default.
• W2795435087 cites W2020422464 @default.
• W2795435087 cites W2020482183 @default.
• W2795435087 cites W2030611116 @default.
• W2795435087 cites W2031246040 @default.
• W2795435087 cites W2040497439 @default.
• W2795435087 cites W2050555000 @default.
• W2795435087 cites W2052204551 @default.
• W2795435087 cites W2093044616 @default.
• W2795435087 cites W2094007374 @default.
• W2795435087 cites W2107443927 @default.
• W2795435087 cites W2108445835 @default.
• W2795435087 cites W2128701654 @default.
• W2795435087 cites W2138489082 @default.
• W2795435087 cites W2172223254 @default.
• W2795435087 cites W2302273984 @default.
• W2795435087 cites W2315029662 @default.
• W2795435087 cites W2336051886 @default.
• W2795435087 cites W2400484325 @default.
• W2795435087 cites W2413823267 @default.
• W2795435087 cites W2588621177 @default.
• W2795435087 cites W2591137745 @default.
• W2795435087 cites W2606213351 @default.
• W2795435087 cites W2612836720 @default.
• W2795435087 cites W2624873234 @default.
• W2795435087 cites W2767447900 @default.
• W2795435087 cites W4236728865 @default.
• W2795435087 cites W4237391818 @default.
• W2795435087 cites W4298302464 @default.
• W2795435087 doi "https://doi.org/10.2147/opth.s163859" @default.
• W2795435087 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5892950" @default.
• W2795435087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29662298" @default.
• W2795435087 hasPublicationYear "2018" @default.
• W2795435087 type Work @default.
• W2795435087 sameAs 2795435087 @default.
• W2795435087 citedByCount "37" @default.
• W2795435087 countsByYear W27954350872019 @default.
• W2795435087 countsByYear W27954350872020 @default.
• W2795435087 countsByYear W27954350872021 @default.
• W2795435087 countsByYear W27954350872022 @default.
• W2795435087 countsByYear W27954350872023 @default.
• W2795435087 crossrefType "journal-article" @default.
• W2795435087 hasAuthorship W2795435087A5008691406 @default.
• W2795435087 hasAuthorship W2795435087A5010511809 @default.
• W2795435087 hasAuthorship W2795435087A5017424349 @default.
• W2795435087 hasAuthorship W2795435087A5026181496 @default.
• W2795435087 hasAuthorship W2795435087A5065829361 @default.
• W2795435087 hasBestOaLocation W27954350871 @default.
• W2795435087 hasConcept C118487528 @default.
• W2795435087 hasConcept C141071460 @default.
• W2795435087 hasConcept C2776268601 @default.
• W2795435087 hasConcept C2776694085 @default.
• W2795435087 hasConcept C2777802072 @default.
• W2795435087 hasConcept C2778257484 @default.
• W2795435087 hasConcept C2778749236 @default.
• W2795435087 hasConcept C2778818243 @default.
• W2795435087 hasConcept C2778844676 @default.
• W2795435087 hasConcept C2780261187 @default.
• W2795435087 hasConcept C2780347916 @default.
• W2795435087 hasConcept C2781100027 @default.
• W2795435087 hasConcept C2908732032 @default.
• W2795435087 hasConcept C71924100 @default.
• W2795435087 hasConceptScore W2795435087C118487528 @default.
• W2795435087 hasConceptScore W2795435087C141071460 @default.
• W2795435087 hasConceptScore W2795435087C2776268601 @default.
• W2795435087 hasConceptScore W2795435087C2776694085 @default.
• W2795435087 hasConceptScore W2795435087C2777802072 @default.
• W2795435087 hasConceptScore W2795435087C2778257484 @default.
• W2795435087 hasConceptScore W2795435087C2778749236 @default.
• W2795435087 hasConceptScore W2795435087C2778818243 @default.
• W2795435087 hasConceptScore W2795435087C2778844676 @default.
• W2795435087 hasConceptScore W2795435087C2780261187 @default.
• W2795435087 hasConceptScore W2795435087C2780347916 @default.
• W2795435087 hasConceptScore W2795435087C2781100027 @default.
• W2795435087 hasConceptScore W2795435087C2908732032 @default.
• W2795435087 hasConceptScore W2795435087C71924100 @default.
• W2795435087 hasLocation W27954350871 @default.
• W2795435087 hasLocation W27954350872 @default.
• W2795435087 hasLocation W27954350873 @default.
• W2795435087 hasLocation W27954350874 @default.
• W2795435087 hasOpenAccess W2795435087 @default.
• W2795435087 hasPrimaryLocation W27954350871 @default.
• W2795435087 hasRelatedWork W1972614420 @default.

• next